You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Litigation Details for Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (N.D.N.Y. 2020)


✉ Email this page to a colleague

« Back to Dashboard


Biologic Drugs cited in Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.
The biologic drugs covered by the patent cited in this case are ⤷  Subscribe and ⤷  Subscribe .

Details for Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc. (N.D.N.Y. 2020)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 External link to document
2020-06-19 1 Complaint Regeneron”) for infringement of U.S. Patent No. 9,220,631 (“the ’631 patent”). …unlawfully uses Novartis’s patented syringe technology and infringes the ’631 patent. …the United States Patent and Trademark Office duly and legally issued the ’631 patent, entitled “Syringe…copy of the ’631 patent is attached as Exhibit A. 13. The ’631 patent is valid and presumed…’631 patent necessary to bring this action, including the exclusive right to enforce the patent in the External link to document
2022-11-07 163 6, 11-13, 17, and 21-25 of U.S. Patent No. 9,220,631 (“the ’631 Patent”); WHEREAS, no trial dates…all claims of the ’631 Patent; WHEREAS, on October 25, 2022, the Patent Trial and Appeal Board…Technology LLC (collectively “Novartis”) brought this patent infringement action accusing Defendant Regeneron…Court. WHEREAS, on October 26, 2021, the Patent Trial and Appeal Board (“PTAB”) instituted an …in IPR2021-00816 finding all claims of the ’631 Patent unpatentable as obvious under 35 U.S.C. § 103; External link to document
2020-07-28 24 Exhibit A 9,220,631 (‘‘the ’631 patent’’). The …properly certain claims of U.S. Patent No. … 1–6 and 11–26 of the ’631 patent, and date of service by the … 19 June 2020 1:20-cv-00690 830 Patent Both District Court, N.D. New York External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.